The study revealed that EZH2 may be an effective predictor of PCa prognosis and immune response.203 Similar results of histone lysine methylation (HLM) regulators ((EZH2, NSD2, and KMT5C) found in an analysis of The Cancer Genome Atlas (TCGA)-PRAD dataset.204 Another study also observed a strong connection between EZH2 expression and macrophage infiltration in breast cancer, suggesting that modulating epigenetic regulation to control macrophage activation is a potential therapeutic strategy for breast cancer.205. Here, NSD2 is linked to breast carcinoma.